Cryosurgery would be An Effective Option for Clinically Localized Prostate Cancer: A Meta-analysis and Systematic Review.
Cryosurgery (CS) has been used on patients with clinically localized PCa for more than 10 years. However, clinical studies evaluating its effectiveness and safety have reported conflicting results. This systematic assessment was performed to obtain comprehensive evidence regarding the potential benefits and safety of CS compared with those of radiotherapy (RT) and radical prostatectomy (RP), respectively. All controlled trials comparing CS with RT or RP and single-arm studies reporting results of CS therapy were identified through comprehensive searches of PubMed, the Cochrane Library and Embase. Ten publications from seven trials, with totally 1252 patients, were included in the meta-analysis, which revealed no significant differences in comparisons of CS vs RT and CS vs RP for overall survival and disease specific survival. However, a significantly lower disease-free survival could be observed for CS than RP. Moreover, a systematic review of literature focusing on comparative data of databases and materials of single-arm trials revealed satisfactory survival results in both primary and salvage CS. Our results showed that cryosurgery would be a relatively effective method for clinically localized prostate cancer with survival results comparable to radiotherapy and radical prostatectomy. However, the large percentage of complications caused by cryosurgery should be carefully monitored.
The Andrology Laboratory, West China Hospital, Sichuan University, 37 Guoxue Xiang, Chengdu, Sichuan 610041, China.|Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 Guoxue Xiang, Chengdu, Sichuan 610041, China.
Liang
L
Gao
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 Guoxue Xiang, Chengdu, Sichuan 610041, China.
Lu
L
Yang
The Andrology Laboratory, West China Hospital, Sichuan University, 37 Guoxue Xiang, Chengdu, Sichuan 610041, China.|Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 Guoxue Xiang, Chengdu, Sichuan 610041, China.
Shengqiang
S
Qian
The Andrology Laboratory, West China Hospital, Sichuan University, 37 Guoxue Xiang, Chengdu, Sichuan 610041, China.|Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 Guoxue Xiang, Chengdu, Sichuan 610041, China.
Zhuang
Z
Tang
The Andrology Laboratory, West China Hospital, Sichuan University, 37 Guoxue Xiang, Chengdu, Sichuan 610041, China.
Feng
F
Qin
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 Guoxue Xiang, Chengdu, Sichuan 610041, China.
Qiang
Q
Wei
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 Guoxue Xiang, Chengdu, Sichuan 610041, China.
Ping
P
Han
The Andrology Laboratory, West China Hospital, Sichuan University, 37 Guoxue Xiang, Chengdu, Sichuan 610041, China.|Department of Urology, Institute of Urology, West China Hospital, Sichuan University, 37 Guoxue Xiang, Chengdu, Sichuan 610041, China.
Jiuhong
J
Yuan
D003452:Cryosurgery; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery*; D016019:Survival Analysis; D016896:Treatment Outcome